Showing 1 - 10 of 627
Persistent link: https://www.econbiz.de/10008575438
Persistent link: https://www.econbiz.de/10008575588
The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting. </AbstractSection> Copyright The Author(s) 2014
Persistent link: https://www.econbiz.de/10010993843
These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator. </AbstractSection> Copyright Springer-Verlag 2013
Persistent link: https://www.econbiz.de/10010993862
In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease. </AbstractSection> Copyright The Author(s) 2012
Persistent link: https://www.econbiz.de/10010993910
Persistent link: https://www.econbiz.de/10010993920
Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2013
Persistent link: https://www.econbiz.de/10010993929
The intervention of dual dispatch defibrillation by ambulance and fire services in the County of Stockholm had positive economic effects. For the cost-benefit analysis, the return on investment was high and the cost-effectiveness showed levels below the threshold value for economic efficiency...
Persistent link: https://www.econbiz.de/10010993942
There were numerous drivers of the different conclusions regarding the cost-effectiveness of trastuzumab, many of which are due to judgements made by the authors when translating data from RCTs. Many of the potential drivers were not identified by the published systematic reviews of economic...
Persistent link: https://www.econbiz.de/10010993957
Without changes in the current policies, pharmaceutical companies will eventually cease responding to the incentives to develop orphan drugs, because they will increasingly be uncertain whether the drugs, if developed, will be reimbursed. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014
Persistent link: https://www.econbiz.de/10010993990